Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Aug;39(8):1748–1751. doi: 10.1128/aac.39.8.1748

Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis.

D P Nicolau 1, M N Marangos 1, C H Nightingale 1, R Quintiliani 1
PMCID: PMC162820  PMID: 7486913

Abstract

Previously, we have shown that a 5-mg/kg of body weight daily dose of aspirin (ASA) caused reductions in the bacterial densities and weights of aortic vegetations in a rabbit model of Staphylococcus aureus endocarditis. We sought to determine (i) whether ASA dosage influences the development of vegetations and (ii) whether ASA given with antimicrobial therapy improves the treatment outcome of infective endocarditis. To study the influence of ASA dosage, animals received either no ASA (control) or oral doses of 2.5, 10, 20, and 50 mg/kg daily. The 2.5- and 10-mg/kg groups had statistically significant reductions in vegetation weight compared with untreated controls. The 10-mg/kg dose also resulted in a significant decrease in bacterial densities compared with those of the controls. Although reductions in weight and bacterial density were observed in other ASA-treated groups, these did not achieve statistical significance. To study the influence of ASA and antimicrobial therapy, the animals received either vancomycin alone or vancomycin with ASA. When ASA was given prior to and during antimicrobial therapy, a significant reduction in vegetation weight was observed. Additionally, the rate of sterilization was directly proportional to this observed reduction in weight. ASA's impact on the reduction of both the bacterial density and the weight of aortic vegetations is a dose-dependent phenomenon. When given with antimicrobial therapy, ASA not only reduces vegetation weight but also improves the rate of sterilization. This study provides additional data regarding the role of ASA in the treatment of endocarditis.

Full Text

The Full Text of this article is available as a PDF (231.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clawson C. C., White J. G. Platelet interaction with bacteria. I. Reaction phases and effects of inhibitors. Am J Pathol. 1971 Nov;65(2):367–380. [PMC free article] [PubMed] [Google Scholar]
  2. Durack D. T., Beeson P. B. Experimental bacterial endocarditis. I. Colonization of a sterile vegetation. Br J Exp Pathol. 1972 Feb;53(1):44–49. [PMC free article] [PubMed] [Google Scholar]
  3. Durack D. T., Beeson P. B., Petersdorf R. G. Experimental bacterial endocarditis. 3. Production and progress of the disease in rabbits. Br J Exp Pathol. 1973 Apr;54(2):142–151. [PMC free article] [PubMed] [Google Scholar]
  4. Garrison P. K., Freedman L. R. Experimental endocarditis I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart. Yale J Biol Med. 1970 Jun;42(6):394–410. [PMC free article] [PubMed] [Google Scholar]
  5. Levison M. E., Carrizosa J., Tanphaichitra D., Schick P. K., Rubin W. Effect of aspirin on thrombogenesis and on production of experimental aortic valvular Streptococcus viridans endocarditis in rabbits. Blood. 1977 Apr;49(4):645–650. [PubMed] [Google Scholar]
  6. Marangos M. N., Onyeji C. O., Nicolau D. P., Nightingale C. H. Disposition kinetics of aspirin in female New Zealand white rabbits. Lab Anim Sci. 1995 Feb;45(1):67–69. [PubMed] [Google Scholar]
  7. Nicolau D. P., Freeman C. D., Nightingale C. H., Quintiliani R., Coe C. J., Maderazo E. G., Cooper B. W. Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis. Infect Immun. 1993 Apr;61(4):1593–1595. doi: 10.1128/iai.61.4.1593-1595.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994 May 5;330(18):1287–1294. doi: 10.1056/NEJM199405053301808. [DOI] [PubMed] [Google Scholar]
  9. Pujadas R., Escrivá E., Fernández F., Jané J., Argimón J., Fava P., Galera M. C. Efecto de diversas dosis de aspirina sobre el desarrollo de la endocarditis trombótica aséptica aórtica inducida experimentalmente en el conejo. Rev Esp Cardiol. 1988 Jan;41(1):31–34. [PubMed] [Google Scholar]
  10. Sullam P. M., Frank U., Yeaman M. R., Täuber M. G., Bayer A. S., Chambers H. F. Effect of thrombocytopenia on the early course of streptococcal endocarditis. J Infect Dis. 1993 Oct;168(4):910–914. doi: 10.1093/infdis/168.4.910. [DOI] [PubMed] [Google Scholar]
  11. Taha T. H., Durrant S. S., Mazeika P. K., Nihoyannopoulos P., Oakley C. M. Aspirin to prevent growth of vegetations and cerebral emboli in infective endocarditis. J Intern Med. 1992 May;231(5):543–546. doi: 10.1111/j.1365-2796.1992.tb00971.x. [DOI] [PubMed] [Google Scholar]
  12. Willard J. E., Lange R. A., Hillis L. D. The use of aspirin in ischemic heart disease. N Engl J Med. 1992 Jul 16;327(3):175–181. doi: 10.1056/NEJM199207163270308. [DOI] [PubMed] [Google Scholar]
  13. Wu T., Yeaman M. R., Bayer A. S. In vitro resistance to platelet microbicidal protein correlates with endocarditis source among bacteremic staphylococcal and streptococcal isolates. Antimicrob Agents Chemother. 1994 Apr;38(4):729–732. doi: 10.1128/aac.38.4.729. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES